Scholars Central

Short communicationPublished 30 Aug 2021

Mesothelin: An Immunotherapy Target

Authors: Wu Wiu De

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

CAR-T cell therapy targeting CD19 has achieved a pace in treatment of B cell malignancies, while different strong malignancies are as yet headstrong for absence of appropriate objective. Lately, an enormous number of studies have looked to discover reasonable focuses with low "on target, off tumor" concern for the treatment of strong/solid tumors. Mesothelin (MSLN), a tumor-associated antigen extensively overexpressed on different dangerous tumor cells, while its expression is the most part restricted to typical mesothelial cells, which is an appealing possibility for targeted treatment. Strategies focusing on MSLN, including antibody-based drugs, immunizations/vaccination and CAR-T treatments, have been evaluated in countless preclinical examinations and clinical trials. Specifically, the improvement of CAR-T treatment has shown incredible guarantee as a therapy for different kinds of malignancies. The safety, efficacy, doses, and pharmacokinetics of significant procedures have been assessed in numerous clinical trials.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Clinical Chemistry and Laboratory Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Chemistry and Laboratory Medicine
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Wu Wiu De”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels